This cohort study examines the response and survival rates associated with ipilimumab-nivolumab therapy in patients with progressive melanoma brain metastases after anti–programmed cell death 1 (anti–PD-1) therapy.
Patients with relapsed ovarian cancer who had germline or somatic BRCA mutations saw greater OS with olaparib, according to data from the LIGHT trial.
Diagnosed with multiple myeloma in 2004, Vicki Jones has lived with her cancer for more than 20 years thanks to chemotherapy and immunotherapy.
Datopotamab deruxtecan approaches approval in Europe as an option for patients with previously treated hormone receptor–positive breast cancer.
Nature Reviews Cancer – Pet dogs with cancer facilitate comparative oncology, enhancing translational research. In this Comment, Lenz and Atherton highlight comparative oncology successes,…
Navtemadlin therapy demonstrated efficacy and safety for patients with JAK inhibitor relapsed/refractory myelofibrosis, as well as improved biomarkers of disease burden, according to data presented…
Panelists discuss how myelofibrosis progresses from its molecular and genetic origins through various clinical manifestations, ultimately informing the development of targeted therapeutic approaches for this…
Panelists discuss Melinda’s experience with her lung cancer diagnosis, including her symptoms, diagnostic tests (such as imaging and blood work), and the progression of her…
This Medical News article is an interview with Eleni Linos, MD, DrPH, who coauthored a study on artificial intelligence’s potential to improve patient-clinician communications.
Sintilimab with neoadjuvant chemoradiotherapy enhanced pCR rates in resectable, locally advanced esophageal squamous cell carcinoma.
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of…
